KRS Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

KRS Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$266K	Hold	1,683	–	–	0.12%	101
2026 Q1	$215K	Hold	1,683	–	–	0.13%	107
2025 Q4	$205K	Buy	+1,683	New	+$193K	0.12%	111
2024 Q4	–	Sell	-2,543	Closed	-$251K	–	122
2024 Q3	$251K	Sell	2,543 -15	-0.6%	-$1.47K	0.18%	103
2024 Q2	$237K	Buy	2,558 +20	+0.8%	+$1.79K	0.18%	108
2024 Q1	$241K	Buy	2,538 +25	+1%	+$2.32K	0.19%	103
2023 Q4	$224K	Buy	+2,513	New	+$187K	0.21%	108
2023 Q3	–	Sell	-2,745	Closed	-$228K	–	116
2023 Q2	$228K	Buy	+2,745	New	+$230K	0.23%	104
2023 Q1	–	Sell	-2,533	Closed	-$210K	–	115
2022 Q4	$210K	Buy	+2,533	New	+$205K	0.29%	101
2022 Q1	–	Sell	-560	Closed	-$62K	–	371
2021 Q4	$62K	Buy	+560	New	+$67.5K	0.05%	216

Other funds holding XBI

MSR

Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Whittier Trust South Pasadena, California $10.2B AUM 33.39% 1-Year Est. Return

AAS

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

WAM

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

RFM

Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return

NHFG

New Harbor Financial Group Worcester, Massachusetts $633M AUM 37.53% 1-Year Est. Return

RAM

Riggs Asset Management Dallas, Pennsylvania $560M AUM 64.94% 1-Year Est. Return

KRS Capital Management's XBI Position: Q2 2026 in Review

KRS Capital Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 1,683 shares worth $266K. The position accounts for 0.12% of the portfolio, ranked #101.

KRS Capital Management first reported a position in XBI in Q4 2021 and has held it in 10 quarters since. 393 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

KRS Capital Management held 1,683 shares of State Street SPDR S&P Biotech ETF worth $266K as of Q2 2026.
KRS Capital Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.12% of KRS Capital Management's portfolio in Q2 2026, its #101 holding.
KRS Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and has held it in 10 quarters since.
393 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on KRS Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.